The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases

E-ISSN： 1875-6638|11|2|104-108

ISSN： 1573-4064

Source： Medicinal Chemistry, Vol.11, Iss.2, 2015-01, pp. : 104-108

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

P-gp Transporter and its Role in Neurodegenerative Diseases

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 2, 2009-02 ,pp. : 209-217

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of psychostimulants on vesicular monoamine transporter function

By Fleckenstein A.E. Hanson G.R.

European Journal of Pharmacology, Vol. 479, Iss. 1, 2003-10 ,pp. : 283-289

Elsevier

Access to resources Recommend Favorite

Binding of -dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific

By Kilbourn M. Lee L. Borght T.V. Jewett D. Frey K.

European Journal of Pharmacology, Vol. 278, Iss. 3, 1995-05 ,pp. : 249-252

Elsevier

Access to resources Recommend Favorite

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments

By Borght T.V. Kilbourn M. Desmond T. Kuhl D. Frey K.

European Journal of Pharmacology, Vol. 294, Iss. 2, 1995-12 ,pp. : 577-583

Elsevier

Access to resources Recommend Favorite

Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2

By Rehavi M. Roz N. Weizman A.

European Neuropsychopharmacology, Vol. 12, Iss. 3, 2002-06 ,pp. : 261-268

Elsevier

Access to resources Recommend Favorite